These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 37906445)

  • 21. Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease.
    Litvinova E; Maury S; Boyer O; Bruel S; Benard L; Boisserie G; Klatzmann D; Cohen JL
    Blood; 2002 Sep; 100(6):2020-5. PubMed ID: 12200361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.
    Hadjis AD; McCurdy SR
    Front Immunol; 2024; 15():1358668. PubMed ID: 38817602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhu J; Chen J
    Mol Biol Rep; 2023 Mar; 50(3):2909-2917. PubMed ID: 36572760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
    Dertschnig S; Gergely P; Finke J; Schanz U; Holler E; Holtick U; Socié G; Medinger M; Passweg J; Teshima T; Stylianou C; Oehen S; Heim D; Bucher C
    Transplant Cell Ther; 2023 Jan; 29(1):41.e1-41.e9. PubMed ID: 36343893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cord Haploidentical Non-In Vitro T Cell Depletion Allogeneic Hematopoietic Stem Cell Transplantation Reduces Relapse of Refractory Acute Leukemia.
    Wang J; Wang Z; Wei W; Zhang W; Zhang T; Cheng H; Fei X; Yin Y; Gu J; Yuan L
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):121-128. PubMed ID: 30205230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
    Cheng Q; Tang Y; Liu F; Li X; Fang D
    Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accumulation of T-cell-suppressive PD-L1
    Baur R; Karl F; Böttcher-Loschinski R; Stoll A; Völkl S; Gießl A; Flamann C; Bruns H; Schlötzer-Schrehardt U; Böttcher M; Schewe DM; Fischer T; Jitschin R; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation.
    Song Y; Zhu Y; Hu B; Liu Y; Lin D; Jin Z; Yin Z; Dong C; Wu D; Liu H
    Front Immunol; 2020; 11():558143. PubMed ID: 33178187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sphingolipid metabolism in T cell responses after allogeneic hematopoietic cell transplantation.
    Tian L; Ogretmen B; Chung BY; Yu XZ
    Front Immunol; 2022; 13():904823. PubMed ID: 36052066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
    Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
    Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
    Koster EAS; von dem Borne PA; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; Halkes CJM; de Wreede LC
    Front Immunol; 2024; 15():1335341. PubMed ID: 38545096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
    De Togni E; Cole O; Abboud R
    Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.